Multiple sclerosis : Immunopathological heterogeneity and its implications
Engelhardt, B. (University of Bern)
Comabella, Manuel (Hospital Universitari Vall d'Hebron)
Chan, A. (University of Bern)
Universitat Autònoma de Barcelona

Date:	2022
Abstract:	MS is the most common autoimmune demyelinating disease of the CNS. For the past decades, several immunomodulatory disease-modifying treatments with multiple presumed mechanisms of action have been developed, but MS remains an incurable disease. Whereas high efficacy, at least in early disease, corroborates underlying immunopathophysiology, there is profound heterogeneity in clinical presentation as well as immunophenotypes that may also vary over time. In addition, functional plasticity in the immune system as well as in the inflamed CNS further contributes to disease heterogeneity. In this review, we will highlight immune-pathophysiological and associated clinical heterogeneity that may have an implication for more precise immunomodulatory therapeutic strategies in MS.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Ressenya ; recerca ; Versió publicada
Subject:	Biomarkers ; Brain barriers immunotherapy ; Multiple sclerosis ; Precision medicine
Published in:	European Journal of Immunology, Vol. 52 Núm. 6 (june 2022) , p. 869-881, ISSN 1521-4141

DOI: 10.1002/eji.202149757
PMID: 35476319

13 p, 2.4 MB

The record appears in these collections:
Articles > Research articles
Articles > Published articles
Articles > Reviews